IMS Health Announces Pricing on Upsized Offering of Senior Notes In Connection with Quintiles IMS Merger DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)

Health Announces Pricing on Upsized Offering of Senior Notes In

Connection with Quintiles IMS Merger

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS

WIRE)--September 14, 2016--IMS Health Holdings, Inc. (NYSE:IMS) today

announced the pricing of its offering of $1.75 billion equivalent in

gross proceeds of senior notes, consisting of $1.05 billion of U.S.

Dollar notes and 625 million of Euro notes to be issued by its wholly

owned subsidiary, IMS Health Incorporated. The offering was upsized from

the previously announced $1.5 billion equivalent aggregate principal

amount. The net proceeds from the notes offering (together with proceeds

from additional term loans and other available cash) will primarily be

used to extinguish certain of the issuer's and Quintiles' existing

indebtedness in connection with the previously announced proposed merger

between IMS Health and Quintiles.

The $1.05 billion U.S. Dollar notes will bear interest at a rate of 5.0%

and will pay interest semi-annually in arrears on April 15 and October

15 of each year beginning on April 15, 2017. The U.S. Dollar notes will

mature on October 15, 2026.

The 625 million Euro notes will bear interest at a rate of 3.5% and

will pay interest semi-annually in arrears on April 15 and October 15 of

each year beginning on April 15, 2017. The Euro notes will mature on

Certain statements in this press release are forward-looking statements.

These statements involve a number of risks, uncertainties and other

factors including the failure to consummate the notes offering and

potential changes in market conditions that could cause actual results

to differ materially.

This press release does not constitute an offer to sell or the

solicitation of an offer to buy the notes. The notes to be offered have

not been, and will not be, registered under the Securities Act of 1933

and may not be offered or sold in the United States absent registration

or an applicable exemption from the registration requirements of the

Securities Act of 1933. The notes are being offered only to qualified

institutional buyers in the United States in reliance on Rule 144A under

the Securities Act of 1933 and outside the United States only to

non-U.S. investors pursuant to Regulation S.

IMS Health (NYSE:IMS) is a leading global information and technology

services company providing clients in the healthcare industry with

end-to-end solutions to measure and improve their performance. Our 7,000

services experts connect configurable SaaS applications to 15+ petabytes

of complex healthcare data in the IMS One cloud platform, delivering

unique insights into diseases, treatments, costs and outcomes. The

company's 15,000 employees blend global consistency and local market

knowledge across 100 countries to help clients run their operations more

efficiently. Customers include pharmaceutical, consumer health and

medical device manufacturers and distributors, providers, payers,

government agencies, policymakers, researchers and the financial

As a global leader in protecting individual patient privacy, IMS Health

uses anonymous healthcare data to deliver critical, real-world disease

and treatment insights. These insights help biotech and pharmaceutical

companies, medical researchers, government agencies, payers and other

healthcare stakeholders to identify unmet treatment needs and understand

the effectiveness and value of pharmaceutical products in improving

overall health outcomes. Additional information is available at www.imshealth.com.

Quintiles (NYSE:Q) helps biopharma and other healthcare companies

improve their probability of success by connecting insights from our

deep scientific, therapeutic and analytics expertise with superior

delivery for better outcomes. From advisory through operations,

Quintiles is the world's largest provider of product development and

integrated healthcare services, including commercial and observational

solutions. Conducting operations in approximately 100 countries,

Quintiles is a member of the Fortune 500 and has been named to Fortune's

list of the "World's Most Admired Companies." To learn more, visit www.quintiles.com.

Important Information about the Transaction and Where to Find It

In connection with the proposed transaction, IMS Health and Quintiles

have filed documents with the SEC, including the filing by Quintiles of

a registration statement on Form S-4 that includes a joint proxy

statement that also constitutes a prospectus of Quintiles. The

registration statement, as amended, was declared effective on August 15,

2016 by the SEC. Quintiles filed the definitive joint proxy

statement/prospectus with the SEC on August 16, 2016. On August 19,

2016, each of IMS Health and Quintiles mailed that document to their

respective shareholders and may also file other documents with the SEC

regarding the proposed transaction. This document is not a substitute

for the joint proxy statement/prospectus or registration statement or

any other document which IMS Health or Quintiles may file with the SEC. Investors

and security holders of IMS Health and Quintiles are urged to read the

registration statement, the joint proxy statement/prospectus and any

other relevant documents, as well as any amendments or supplements to

these documents, carefully and in their entirety when they become

available because they will contain important information. Investors

and security holders may obtain free copies of the registration

statement and the joint proxy statement/prospectus and other documents

filed with the SEC by IMS Health and Quintiles through the web site

maintained by the SEC at www.sec.gov or by contacting the

investor relations department of IMS Health or Quintiles at the

Click here to subscribe to Mobile Alerts for Quintiles.

IMS Health Media Relations

IMS Health Investor Relations

Quintiles Media Relations

Quintiles Investor Relations